- This topic is empty.
Viewing 1 post (of 1 total)
-
AuthorPosts
-
July 27, 2026 at 8:30 pm #4465
Admin
KeymasterA curated, no-fluff list of primary sources and reputable coverage for anyone doing serious Retatrutide research. This is meant to be a living resource — reply with a peer-reviewed study, a ClinicalTrials.gov listing, a conference abstract, or reputable science journalism, and we’ll keep it current. Please don’t post promotional or vendor content here; there are other threads and the Supplier Transparency forum for that.
Peer-reviewed studies
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (New England Journal of Medicine, 2023)
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
ClinicalTrials.gov listings
- TRIUMPH-1 — Retatrutide in obesity/overweight (NCT05929066)
- TRANSCEND-T2D-1 — Retatrutide in type 2 diabetes (NCT06354660)
- TRIUMPH-Outcomes — cardiovascular and kidney outcomes (NCT06383390)
- Retatrutide vs. tirzepatide head-to-head trial (NCT06662383)
Official company announcements
- Eli Lilly investor newsroom: TRIUMPH-1 Phase 3 topline results
- Eli Lilly investor newsroom: TRANSCEND-T2D-1 Phase 3 topline results
Reputable science and medical journalism
If you find something worth adding — especially peer-reviewed data or ClinicalTrials.gov updates — reply below with the link and a one-line summary of what it shows.
This is a reference list of published research and public reporting, not medical guidance.
-
AuthorPosts
Viewing 1 post (of 1 total)
- You must be logged in to reply to this topic.